Dr. Karen Liu is a founding partner of 3E Bioventures Capital, a healthcare focused venture capital firm. Prior to 3E Bioventures, Dr. Liu was a partner at Kaiwu Capital in charge of healthcare investment from 2011-2015 and before that, was Managing Director at CRCI Capital from 2007-2011, also in charge of healthcare investment. In 2006, she co-founded Shenogen Pharma, a company developing innovative liver cancer therapeutics, and was its first angel investor. From 2000-2004, she was an entrepreneur and senior team member of 3721, an Internet search company that eventually was sold to Yahoo in early 2004. She also worked as a consultant at McKinsey & Company from 1998-2000. Dr. Liu has been active in China healthcare venture investment since 2006. Her investments include companies in devices, diagnostics and drugs, and increasingly she invests in the cross-sector innovations between medtech and information technology. Dr. Liu received her PhD in Immunology from Harvard University, a Master of Medical Sciences degree from Harvard University, and Bachelor of Sciences degree from Cornell University. She also received an EMBA degree from CKGSB – Chungkong Graduate School of Business in China.